What is Zacks Research’s Forecast for JAZZ Q1 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) – Stock analysts at Zacks Research raised their Q1 2025 EPS estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 18th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will post earnings of $3.51 per share for the quarter, up from their prior forecast of $3.17. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

JAZZ has been the subject of a number of other research reports. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $140.57 on Friday. The company has a market capitalization of $8.54 billion, a price-to-earnings ratio of 19.80, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a 50 day moving average of $131.07 and a 200 day moving average of $121.46.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $25,000. Quadrant Capital Group LLC boosted its holdings in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP boosted its holdings in Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $28,000. Finally, Allianz SE purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,022,825 over the last ninety days. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.